RNA-Based Therapeutics and Vaccines on November 10-12, 2026 in Incheon, Republic of Korea

South Korea's mRNA ecosystem is rapidly advancing, fueled by progress from companies like GC Biopharma and EyeGene in clinical-stage vaccines. Also, with the growing momentum of ARPA-H initiatives focused on personalized mRNA cancer therapies and strong government backing continues to drive the development of safer, more effective RNA-based medicines.

Amid this innovation, the World RNA-Based Therapeutics and Vaccines Summit returns to South Korea for its second year, highlighting breakthroughs in mRNA design, therapeutic pipelines, targeted delivery, and solutions to key manufacturing and analytical challenges. This is your chance to de-risk your program strategies, unlock insights from international leaders, and forge networks to develop better RNA medicines for patients faster.

As part of the World Advanced Therapeutics Summit South Korea organized by Hanson Wade, this event offers a platform for cross-learning and connections with experts working in cell and gene therapies and together establish South Korea as a global hub for advanced biopharma innovation.

URLs:

Tickets: https://go.evvnt.com/3703492-2?pid=10008

Brochure: https://go.evvnt.com/3703492-3?pid=10008

Time: 8:30 AM - 3:15 PM

Prices:

Drug Developer Pricing - Conference + 2 Workshops: USD 2199.00,

Drug Developer Pricing - Conference + 1 Workshop: USD 1999.00,

Drug Developer Pricing - Conference Only: USD 1799.00,

Academic Pricing - Conference + 2 Workshops: USD 1899.00,

Academic Pricing - Conference + 1 Workshop: USD 1749.00,

Academic Pricing - (Conference Only: USD 1599.00,

Service Provider Pricing - Conference + 2 Workshops: USD 5149.00,

Service Provider Pricing - Conference + 1 Workshop: USD 4499.00,

Service Provider Pricing - Conference Only: USD 3849.00

Speakers: Bo Ying, Chief Executive Officer, Abogen Bioscience, Kee-Jong Hong, Professor, Gachon University School of Medicine, Takeshi Kuboyama, Strategy Head of Research, AceRNA Technologies, Wonil Kim, Chief Scientific Officer, Aston Sci, Kunwoo Lee, Chief Executive Officer, BreezeBio, Peter Weinstein, Chief Executive Officer, Circurna, Kosuke Nakamoto, Principal Scientist, Eisai, Sunjong Kwon, Head of R and D Centre, EyeGene, Jaesung Jung, Team Leader - mRNA Research, GCBiopharma, Jaehyun Choi, Chief Executive Officer, Genexine, Seihwan Jeong, Project Leader – Cancer Immunotherapy, LG Chem, Kug Hwa Lee, Director, MediciBIO, Yasumasa Ohta, mRNA Technology Leader, Meiji Seika Pharma, Chi-Kang Tseng, Associate Professor, National Taiwan University, Dal-Hee Min, Chief Technology Officer and Professor, Lemonex Bio and Seoul National University, Pieter Swanepoel, Director, Technical and Commercial, RNA Australia, Kyung Hyun Lee, Chief Researcher, Rznomics, Saswata Karmakar, Director of Chemistry, mRNA Centre of Excellence, Sanofi, Hyung-Jun Im, Associate Professor and Chief Scientific Officer, Seoul National University and Portal, Dan Peer, Professor, Tel Aviv University, Hoon Sang Lee, Chief Strategy Officer, The RIGHT Foundation, Jeonghwan Kim, Assistant Professor, Yeungnam University